Quantitative Analysis of ADC Components - Ligand Binding Assay (LBA) and LC-MS/MS

There are both large and small ADC molecules. A variety of biological analysis methods and platforms are needed to analyze the diversity of ADCs.

Survey Reveals Older Adults Eager to Get Ahead of Alzheimer's and Other Dementias; Industry Lags

92% of participants want to know about Alzheimer’s early according to new Linus Health report

Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs

Driving more complete decisions for biopharmaceutical companies with modern digital pathology

Proscia Announces Major Expansion In Preclinical R&D To Drive Faster Drug Safety Decisions

Flagship software platform further unifies pathology workflows and data across the R&D value chain

LIQUID STABLE CLINICAL ENZYME CALIBRATION VERIFIERS FOR AMYLASE & LIPASE TESTING NOW AVAILABLE FROM VERICHEM

VERICHEM LABORATORIES now offers multi-level calibration verification materials for amylase and lipase activity as part of its liquid stable, ready-to-use Enzyme ER™ Verifier Kit.

Clinical Pharmacology of Antibody-Drug Conjugates

BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners

In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands.

Inizio strengths senior team with DE&I appointment

International strategic health and life science specialists Inizio have increased their organizational-wide focus on diversity, equity, and inclusion with the appointment of Stefanie Christmas as their new Global Head of Diversity, Equity & Inclusion (DE&I).

BioIVT to Highlight its Drug-Drug Interaction and ADME Research Expertise at the SOT Annual Meeting and ToxExpo

It will provide strategies to de-risk each stage of the R&D pipeline, with particular focus on regulatory drivers, investigatory objectives, and practical concerns that are relevant to toxicologists.

Recipharm's Arranta Bio expands RNA process development capacity by 50 percent to meet increased customer demand

Arranta Bio, a Recipharm company and leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, has announced that it has doubled capacity at its Watertown, MA facility for process development services supporting RNA therapeutics.

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health’s Mural Link™ platform and ProofPilot’s platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Implanting a Better Future: Navigating the Changing Dynamics of the Medical Implant Industry

The COVID-19 pandemic has had a major impact on the implant industry, both positively and negatively. Here are some of the main effects:

New study shows low endotoxin biomaterials improve reliability of 3D in vitro models; Pave the way for reduced animal testing

Darling Ingredients’ health brand Rousselot, the global leader1 in collagen-based solutions, announced today that a new study has found that utilization of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.

Clinion Launches Revolutionary AI-Powered Medical Coding Solution for Clinical Trials

[London, UK] - Clinion, a leading provider of eClinical solutions, has announced the launch of its new AI-powered medical coding solution. This innovative solution is designed to transform the medical coding process for clinical trials, offering a faster, more efficient, and more accurate way to code medical data. Medical coding is a critical component of clinical trials, as it enables researchers to accurately capture and analyze medical data. However, the process of medical coding can be time-consuming, error-prone, and costly, often leading to delays in the clinical trial process. Clinion's new AI Medical Coding is set to revolutionize the clinical trial process by leveraging the power of artificial intelligence to automate medical coding. The solution uses advanced machine learning algorithms to analyze medical data and assign the appropriate medical codes, significantly reducing the time and effort required for manual coding. The solution also provides real-time feedback to clinical trial teams, allowing them to make data-driven decisions more quickly and efficiently. With improved accuracy and speed, Clinion's medical coding solution enables clinical trial teams to deliver high-quality results and insights faster than ever before. "We are thrilled to launch AI Medical Coding, which we believe will transform the clinical trial process," said Manuj Vangipurapu, CEO of Clinion. "By harnessing the power of AI, we can provide clinical trial teams with a faster, more efficient, and more accurate way to code medical data. This will enable our customers to make data-driven decisions more quickly and effectively, ultimately accelerating the drug development process and bringing new treatments to patients faster." Clinion's medical coding solution is the latest addition to its suite of eClinical solutions, which include EDC, RTSM, ePRO, eConsent and CTMS. sWith over 500+ clinical trials successfully conducted using its solutions, Clinion is the go-to partner for companies seeking to streamline their clinical trial process and bring new treatments to market faster. For more information on Clinion's new AI-powered medical coding solution, please visit clinion.com. About Clinion Clinion is a global clinical technology company that offers AI-enabled eClinical solutions consisting of EDC, RTSM, CTMS, eCOA and Document Automation that cover the entire clinical trial lifecycle. Clinion is committed to innovating the future of clinical trials through AI/ML and empowering its partners to manage trials more efficiently at lesser costs. For more information, please visit www.clinion.com.

Clinical Trial Technology Trends: The Top 5 Innovations Shaping Clinical Trials in 2023

Discover the top 5 clinical trial technology trends in 2023. From wearables to AI, Digital Patient engagement tools and techniques that are shaping the future of clinical research

Orbita and Isabel Healthcare improve provider websites, patient experience

Orbita, a provider of virtual assistants for healthcare, announced a partnership with Isabel Healthcare that will improve patients’ digital experiences, helping them find the right care for their individual health circumstances.

ARIA MARKETING AND ESCALATE PR PARTNER TO BRING THE MOST COMPREHENSIVE MARKETING OFFERING TO TECH AND HEALTHCARE

Confluence of Industries Requires Nimble, Creative, and Cross-functional Expertise that Flexes and Scales For Pure-play and Multi-line Businesses

Optical Brighteners, Plasticizers, and Antioxidants as Polymer Stabilizers

Biopharma PEG To Attend PEGS Boston Summit 2023

Huateng Pharma Announced To Present CPhI North America In April 2023